ææ°ãã¥ãŒã¹
åçå»çã§ã«ãããšæ¥æ¬ããªãŒãããæè¡é©æ°
Author
Master
Date
2015-03-10 05:46
Views
903
äž¡åœãç°ãªãæŠç¥ãäžã€ã®ç®æšïŒã¢ãã¬ãã·ã³ã°äžæ²»ã®ç ç¶ã
ã«ãããšæ¥æ¬ã¯ãã®å¢çå åçå»çç£æ¥ã®çºå±ã«æããã«ç°ãªãããè£å®çãªãã¹ãåã£ãŠããŸãããã®ãã¹ãç°ãªããããããªããã圌ãã®æŽ»åã¯ãææ°é¢æ°çãªæé·ãèŠèŸŒãŸããŠããã°ããŒãã«ç£æ¥ã®å°æ¥ã«å€§ããªåœ±é¿ãæã£ãŠããŸãã
åçå»çã®ãªãŒããŒã·ãããžã®æ¥æ¬ã®åãçµã¿ã¯ãåœã®çµæžã掻æ§åããããã®å®åæäžéŠçžã®ããžã§ã³ã«ãã£ãŠæ¯ããããŠããŸãããã€ãŸããçµæžåŸ©èã¯$ 1å幹现èç 究ã®ããã®è³éã§10幎以äžç±³åœãå«ããæ¥æ¬ã§å ç¢ãäžçæå 端ã®åçå»çç£æ¥ã®çºå±ããµããŒãããããã®ããªã·ãŒãå«ãŸããŠããŸãã
æ¥æ¬ã®åãçµã¿ã¯ãåœã®çµæžçå©çã«ãã£ãŠé§åãããéšåã§ãããããããã¯å€§ãããæ¥éã«é«éœ¢åæ¥æ¬ã®äººå£çµ±èšçã«æ°è¬ãããããã«ã€ããŠæ ¹æ¬çã«ã§ãã
ãæ¥æ¬ã¯æ¥æ¬åžå Žãžã®å€åœäººã®æ²»çè¬ãããããããšã«ãã£ãŠãæ¥æ¬ã®è£œåãéçºããåœå ã®æè¡é©æ°ãšé åçãªå€åœäŒæ¥ã奚å±ããããšã«ãããåçå»çæ¥çã§ã®ãªãŒããŒã·ããã確ç«ããããšããŠãããããŠãŒã倪平æŽã«ãã瀟ã®ããçäžæŠè€ãããŒãæ¥æ¬ä»£è¡šã "è¿°ã¹ãŠç§ãã¡ã®åœã®æå°è ã®äœ¿åœã¯ãåçå»çã®çã®ãå®çšçãªããã¬ãŒã¯ã¹ã«ãŒã®ããã®éãéãããšã§ããç§ã®äŒç€Ÿã¯ç©æ¥µçã«ãRepliCelã©ã€ããµã€ãšã³ã¹ããã³ä»ã®ãããªãæ¥æ¬ä»¥å€ã®äŒæ¥ãšååããŠæ¥æ¬ã®æè³å®¶ãæŠç¥çããŒãããŒéã®äžæ¹ããŒãããŒã·ãããæ§ç¯ããŸããããã³æ²»çã®éçºè ã "
ãåçå»çã现èæ²»çåéãäžçäžã§æ¥éã«å€åããŠãããããã€ã±ã«æãããã³ãã®ããŠã³ã¿ãŠã³ã«ããåçå»çã®å®çšåïŒCCRMïŒã®ããã®ã»ã³ã¿ãŒã®æé«çµå¶è²¬ä»»è ïŒCEOïŒã¯è¿°ã¹ãŠããŸãã ãã©ã®ãããªæ¥ââæ¬ã§èµ·ãã£ãŠããããšã¯å¢ãããã®æ¥çã§æ§ç¯ããŠãããã®äžäŸã§ããäŒæ¥ãæè¡ã財åããã³èšåºã®çºå±ã«éåžžã«ãéåžžã«è¿ éã«èµ·ãã£ãŠããŸããã
åçå»çã¯ãç æ°ã®çŽ°èãçµç¹ãèåšã修埩åçãŸãã¯äº€æããããã«ã现èãçäœææãååã®åã掻çšããããšãç®æããŠããŸããä»æ¥ã¯äžçã§æãç Žå£çãã€è²»çšã®ãããçŸæ£ãŸãã¯æ ¢æ§çç¶ã®ããã€ãããæ²»çã管çããã³ããããæ²»ãããã«ææã§ãã
æ¥æ¬ã®æŠç¥ã®éèŠãªèŠçŽ ã¯ã现èããŒã¹ã®æ²»çæ³ã«é¢é£ããç£ç£ãæ¿èªãèšåºéçºããã³è£œé ããã»ã¹ã®åšãã«èŠå¶æ¿çãå€æŽããŠããŸãã ãæ¥çã®æ¹ã®ããã«ãããã¯åçã«åçå»çã®é¢šæ¯ãå€æŽããããšãçŽæããªãŒãããåãçµã¿ã§ããããæã¯è¿°ã¹ãŠããŸãã ãæ¥æ¬ã¯ã幹现èåœå®¶ã«ãªãããã«èŠå¶åœå±ã®æ¿èªã«é©åœãèµ·ãããŠããŸããã
ã«ããã¯åçå»çç§åŠã«ããããã®åŒ·åºŠã®ç¹ã§åçããç¬èªã®æå°ç圹å²ãæã£ãŠã圌ã¯ãã«ããã¯æ¥æ¬ã®éåã®å ã®äžã§éåžžã«å©çã«ãªãåçå»çã®åšãã®ãã¬ã€ã§ããã€ãã®éåžžã«æ°èŠã§è²ŽéãªæŠç¥ãæã£ãŠããŸãã "ãè¿œå ããŸã
CCRMã¯ãåçå»çç§åŠãšã«ããã§å©çšå¯èœãªç¥ç財ç£ã®å¯ãåæ¥åã«éèŠãªåœ¹å²ãæãããŠããŸããããã¯ãæ°äŒç€Ÿãèšç«ãŸãã¯ãã®ä»£ããã«æè¡ãéçºããããŒãããŒãèŠã€ããããšã®ããããã«ãã£ãŠéæãããŠããŸãã 2011幎ã®åµæ¥ä»¥æ¥ãCCRMã¯ãåŠçãšã®é¢ä¿ã確ç«ããŠããäžçäžãã40以äžã®äŒæ¥ã®æ£åŒãªæ¥çã®ã³ã³ãœãŒã·ã¢ã ãäœæãã6ã€ã®ã³ã¢ã«ããã®æ©é¢ã®ããŒãããŒãåŸãŸããã
åçç£æ¥ã®äž»èŠã»ã¯ã¿ãŒã代衚ããã³ã³ãœãŒã·ã¢ã ã®ã¡ã³ããŒã¯ãåçå»çã幹现èçç©åŠããå¿èç ãç³å°¿ç ãåŒåžåšçŸæ£ãèé«æå·ãªã©ã®çç¶ãæ²»çããåçå»çã®ããã®äžççã«æåãªã»ã³ã¿ãŒã®McEwenã®ã»ã³ã¿ãŒããããŸããã«ããã¯ãŸããã«ããã®å¹¹çŽ°èãããã¯ãŒã¯ãåèšåºå¹¹çŽ°èç 究ãåºçç©ã®äžã§æãé©ç°çãªãããã¥ãŒãµãŒã®äžäººã«å®¶ã§ãã
CCRM to-date has performed due diligence on 200 cell therapy technologies from Canada and around the world. These include work by Canadian leaders such as Induce Biologics, Sernova, TRT, RepliCel Life Sciences, Insception Lifebank, Octane, Northern Therapeutics, Interface Biologics, Stemcell Technologies, Actium Research, Hemostemix and more.
Now the focus is on building a third network which is one of investors, May says. âThe plan is to launch investment vehicles specifically focused on regenerative medicine to finance commercial opportunities in Canada. This final piece is really important in supporting commercialization and creating manufacturing capability in Ontario. When this happens, Canada will hold a unique leadership position in the world.â
CCRM is a world-class example of the efforts to create pathways for regenerative medicine commercialization, says Lee Buckler, Vice President, Business and Corporate Development, for RepliCel Life Sciences (TSXV: RP) in Vancouver. âThey are really bringing the whole industry to Canada by creating an infrastructure for great research, development, production, and commercialization.â
RepliCelã¯ããã®æ¥éã«æ°èã®æ©äŒã掻çšããããã«æ¥æ¬ã®ç£æ¥çãšã®æ£åŒãªé¢ä¿ãäœæããããã«ãäžçã§æåã®ãã¡ãããŠããåçå»çã®ã€ãããŒã¿ãŒã§ãã 2013幎ã«ã¯ãè±æ¯çãæ²»çããããã«ïŒæ£è èªèº«ã®æ¯å ããæ¡åãã现èãçšããŠè£œé ããããã®ïŒã®èªå®¶çŽ°èçæ³ã®å®çšåã®ããã«è³çå 瀟ãšäž»èŠãªå¥çŽãç· çµããŸãããå¥çŽã¯ãç¹å®ã®ã¢ãžã¢è«žåœã®ããã«è³çå ã«ãRepliCelã§æãå é²çãªè£œåãRCH-01ã®ããã®ç¬å çã©ã€ã»ã³ã¹ãä»äžããŸããã
ç 究éçºã®ããã®æ°æŽäžå³¶è°·ãè³çå ã®ããŒãå·è¡åœ¹å¡ã¯ãæ¥åžžç掻ã®äžã§çŸãããäœæããè³çå ã®äœ¿åœã§ããããšã³ã¡ã³ããè±æ¯çãæã€äººã ã®èŠãã¿ã軜æžããããã«ãæã ã¯ã髪ã®ç 究ã«é·å¹Žæ§ããŠããŸãããè³çå ã¯çŸåšãæ¥æ¬ã®ãã¢ç 究ã®äž»èŠãªèšåºãªãããªã³ãªãŒããŒã®ç£ç£ã®äžã§åè±æ¯çã®æ²»çã®ããã®RCH-01ã®èšåºèª¿æ»ç 究ãèµ·åããæºåãããŠãããç§ãã¡ã®ç 究掻åããåŸãç¥èãæè¡ã䜿çšãããã圌ã®æèŠã§ã¯ã "æ¥æ¬ã®æ°ããåçå»çæ³ã§ã¯ãè³çå ãªã©ã®æ¥çããŒãããŒãæ°ããªåçæ²»çæ³ãéçºããããã®èšåºæå°ã®äžãèšåºç 究ã«åå ããããšãã§ããŸããæã ã¯ãæã ã®åªåãäžå±€ã®ä¿é²ãšæ¥æ¬ã®åçå»çã®çºå±ã«ã€ãªããããšãé¡ã£ãŠããŸããã
æ¥æ¬ã®æ°ããèŠå¶ã2014幎11æã«å®æãããåã«è³çå ãšã®å¥çŽããŸããªã調å°ãããã®ã§RepliCelã¯ãæ¥æ¬ãããã¯ã©ãŒããŒãã®ãŠããŒã¯ã§åŒ·åãªç«¶äºåãä¿æããŠããŸãã
圌ã¯RepliCelã¯ãæ¥æ¬ã®ããŒãããŒãšã®ããã€ãã®å€åœçŽ°èçæ³äŒç€Ÿã®äžã€ã§ãããæ¥æ¬ã®ç©æ¥µçãªè£œé ãããããªã³ãã§ããã«å°ããªã°ã«ãŒãã®äžã€ãšããŠã©ã³ã¯èšããŸãã ãæã ã¯ãŸããæ°ããªèŠå¶ã®äžã§ã®æ¥æ¬ã®ããŒãããŒãšã®èšåºè©Šéšãéå§ããæ å¢ãæŽããŠãæåã®å€åœçŽ°èæ²»çäŒç€Ÿã®äžã€ã§ãããšèããŠããŸããã
å瀟ã¯ãŸããç©æ¥µçã«æŽåœ¢å€ç§ïŒè ±ä¿®åŸ©ïŒããã³ç®èç§ïŒç®èã®è¥è¿ãïŒã¢ããªã±ãŒã·ã§ã³çšã®ãã€ãã©ã€ã³å ã®ä»ã®è£œåã«ã€ããŠãåæ§ã®ããŒãããŒã·ããã確ç«ããããã«ãæè³å®¶ãæœåšçãªããŒãããŒã«ä¿åãããŠããŸãã
ããã¯ã©ãŒã¯CCRMåŽã®å ±åäœæ¥ãšçµã¿åãããåçå»çã«ãããã«ããã®æ·±ãã«ãŒãã¯ãäžççãªåæ¥åã®æ©äŒãè¿œæ±ããŠãããããªRepliCelãªã©ã®äŒæ¥ã®èŠéãã®ããã«ããåå ãšèããŠããŸãã
æ¥æ¬ã¯CCRMã®ã°ããŒãã«ã³ã©ãã¬ãŒã·ã§ã³ã®åãçµã¿ã®å¯äžã®çŠç¹ã§ã¯ââãããŸããããæã¯ãåçå»çã®ãªãŒããŒãšããŠã«ããã®æªæ¥ãžã®ç€ã§ãããšèšããŸãã ãæ¥æ¬ãè¡ã£ãŠããæãé©æ°çãªããšã®äžã€ã¯ã现èæ²»çäŒæ¥ãæ¡ä»¶ä»æ¿èªãååŸããããè¿ éã«åžå Žã«èªç€Ÿè£œåãæåããããšãå¯èœã«ããåçå»çã®ããã®æ°ããçµè·¯ãäœæããããšã§ããäŒæ¥ãéçºããå®çšåã®ããã«æ¥æ¬ã«æè¡ãããããããã®åžå Žãžã®ã¢ã¯ã»ã¹ãè¿ éåããããšã¯éåžžã«å€§ããªã¢ãããŒã·ã§ã³ãäœæããŸããããã®éšåã®æè³å®¶ã¯ãåãæ©äŒãèŠãŠããã®å¢ãã«æ§ç¯ããæ¹æ³ã暡玢ããŠããŸããã
ãã®å¢ãã¯äžççã«çŽ°èæ²»çç 究ãžã®æè³ã«çæãããŠããé¢å¿ã®ææšã§ãããææ°ã¯è¿°ã¹ãŠããŸãã ãåè¶æ§ã®ä»ã®ã°ããŒãã«ã»ã³ã¿ãŒãæ¥æ¬ãªã©ã®åœã«ãããæ°ããªèŠå¶çµè·¯ãšCCRMã®ãããã¯ãŒãã³ã°ã®åªåã¯ãäŒæ¥ãåžå Žã«æœåšçã«æåœè£œåãæäŸããããã«ãè€æ°ã®åœã§åããŠãããã®çŽ æŽãããäŸã§ããã